Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

OKUR OnKure Therapeutics Inc.

Price (delayed)

$2.89

Market cap

$39.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.94

Enterprise value

-$56.66M

Highlights
OKUR's EPS has surged by 91% year-on-year and by 9% since the previous quarter
The quick ratio has plunged by 63% YoY but it has grown by 4.6% from the previous quarter
The equity is down by 13% since the previous quarter but it is up by 12% year-on-year
OnKure Therapeutics's net income has shrunk by 102% YoY and by 14% QoQ

Key stats

What are the main financial stats of OKUR
Market
Shares outstanding
13.51M
Market cap
$39.05M
Enterprise value
-$56.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$61.82M
Net income
-$60.17M
EBIT
-$59.87M
EBITDA
-$59.08M
Free cash flow
-$44.18M
Per share
EPS
-$13.94
EPS diluted
-$13.94
Free cash flow per share
-$3.29
Book value per share
$6.75
Revenue per share
$0
TBVPS
$7.44
Balance sheet
Total assets
$99.88M
Total liabilities
$9.23M
Debt
$955,000
Equity
$90.65M
Working capital
$89.39M
Liquidity
Debt to equity
0.01
Current ratio
11.17
Quick ratio
11
Net debt/EBITDA
1.62
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-64.8%
Return on equity
-69.7%
Return on invested capital
-513%
Return on capital employed
-65.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OKUR stock price

How has the OnKure Therapeutics stock price performed over time
Intraday
7.43%
1 week
18.44%
1 month
15.6%
1 year
N/A
YTD
-66.4%
QTD
-32.79%

Financial performance

How have OnKure Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$61.82M
Net income
-$60.17M
Gross margin
N/A
Net margin
N/A
OnKure Therapeutics's operating income has plunged by 102% YoY and by 14% from the previous quarter
OnKure Therapeutics's net income has shrunk by 102% YoY and by 14% QoQ

Price vs fundamentals

How does OKUR's price correlate with its fundamentals

Growth

What is OnKure Therapeutics's growth rate over time

Valuation

What is OnKure Therapeutics stock price valuation
P/E
N/A
P/B
0.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OKUR's EPS has surged by 91% year-on-year and by 9% since the previous quarter
The P/B is 46% less than the last 4 quarters average of 0.8
The equity is down by 13% since the previous quarter but it is up by 12% year-on-year

Efficiency

How efficient is OnKure Therapeutics business performance
OnKure Therapeutics's return on invested capital has shrunk by 178% QoQ
OKUR's ROA has dropped by 117% year-on-year and by 9% since the previous quarter
OKUR's ROE is down by 33% year-on-year and by 11% since the previous quarter

Dividends

What is OKUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OKUR.

Financial health

How did OnKure Therapeutics financials performed over time
The total liabilities has soared by 172% YoY but it fell by 17% QoQ
OnKure Therapeutics's current ratio has plunged by 63% YoY but it has increased by 4.1% from the previous quarter
OKUR's debt is 99% smaller than its equity
The equity is down by 13% since the previous quarter but it is up by 12% year-on-year
OKUR's debt is down by 12% since the previous quarter but it is up by 5% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.